In GBM it could be particularly helpful to further characterize the still heterogeneous proneural sub-type where low levels of PATZ1 correlate with worse outcome in both overall and progression-free survival curves, independently from other known prognostic factors, such as MGMT promoter methylation and age of diagnosis [31]. The gene discussed is MGMT; the disease is glioblastoma.